Related Experiment Video

Updated: Jul 14, 2026

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
09:16

Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy

Published on: September 11, 2015

[Dermatological side effects of epidermal growth factor receptor inhibitors]

Bénédicte Doebelin1, Arnaud Ly, Carole Allombert

  • 1Service de dermatologie, Hôpital Edouard Herriot, Lyon (69).

Presse Medicale (Paris, France : 1983)
|July 3, 2007
PubMed

Insights

Epidermal growth factor receptor (EGFR) inhibitors treat cancer but cause skin issues like papulopustular eruptions and paronychias. These side effects correlate with treatment effectiveness, suggesting a link to tumor regression and survival.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Epidermal growth factor receptors (EGFR) are crucial in tumor proliferation.
  • Anti-EGFR therapies offer promising cancer treatment options.
  • Dermatological side effects are common in patients receiving anti-EGFR treatment.

Purpose of the Study:

  • To investigate the incidence and characteristics of dermatological side effects associated with anti-EGFR cancer therapy.
  • To explore the correlation between the severity of skin reactions and treatment outcomes.

Main Methods:

  • Observational study of patients undergoing anti-EGFR therapy.
  • Documentation of dermatological side effects, including papulopustular eruptions and paronychias.
  • Correlation analysis between side effect intensity and tumor regression/survival rates.

Main Results:

  • Papulopustular follicular eruptions affect 45-85% of patients.
  • Paronychias develop after several weeks, causing pain and functional impairment.
  • A positive correlation was observed between eruption intensity, tumor regression, and patient survival.

Conclusions:

  • Anti-EGFR therapy frequently induces significant dermatological side effects.
  • The severity of these skin reactions may serve as a predictive biomarker for treatment efficacy and patient survival.
  • Managing these side effects is crucial for patient compliance and therapeutic success.

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Reticular Dermis01:15

Reticular Dermis

The papillary and reticular dermis are the two layers of the dermis. They are made of connective tissue with fibers of collagen extending from one to the other, making the border between the two somewhat indistinct. The dermal papillae extending into the epidermis belong to the papillary layer, whereas the dense collagen fiber bundles below belong to the reticular layer.
Reticular Layer
Underlying the papillary layer is the much thicker reticular layer, composed of dense, irregular connective...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...